Skip directly to content

Esiet sveicināti Pfizer Latvija

Welcome to Pfizer Latvia!

Working Together for a Healthier World®

About Pfizer

Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.

We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.

To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.

Corporate overview

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Corporate responsibility

At Pfizer, we believe that only by keeping our core values at the center of everything we do can we advance our mission to improve health for people around the world and create continued value for the people who affect and are affected by our business.

As such, we are committed to upholding the highest ethical standards in everything from research and development to sales and marketing. We are focused on nurturing a workplace of diversity and inclusion for our colleagues, maintaining a customer-centered approach to our business, and giving back to the communities where we work and live. And we are dedicated to making continual progress in innovation by investing our resources wisely and engaging collaboratively with our partners around the world.

Pfizer Latvia

Pfizer is present in Latvia since 1997. Currently more than 15 colleagues are employed in the Latvian organization. Pfizer office is located in Riga and our Medical representatives’ colleagues are covering the whole territory of the country.

The company in Latvia is divided into two  Business Units each of which works in different areas of medicine. These Business Units are: Pfizer Innovative Health (PIH) and Pfizer Established Health (PEH) business unit. In Latvia Pfizer Innovative Health includes five  business groups – Inflammation & Immunology, Internal Medicine (neuroscience and pain, and cardiovascular and metabolic), Oncology, Rare Disease and Vaccines.

European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code

We regularly work with healthcare professionals (HCPs) and healthcare organisations (HCOs) who advise us on a range of topics such as medicines development, the role of a medicine in a patient treatment pathway; health economics and clinical best practice. These working relationships are essential to gaining the real-world information we need in order to deliver treatment choices that improve the health of patients and to share information that may be relevant to clinical decision making.

We want people to know, and understand, what we do and how we do it. We are committed to transparency about how we operate as a business and about the relationships we have with HCPs and HCOs. Sharing information about these relationships in a straightforward and open way will, we hope, help explain the critical value these relationships bring to patient management.

We believe that transparency is essential to building and maintaining confidence in us and in our medicines and strongly support the work being done by The European Federation of Pharmaceutical Industries and Associations (EFPIA) to improve transparency across the pharmaceutical industry.

The EFPIA Disclosure Code provides a common basis for reporting across Europe in relation to transfers of value. For more information on this Code visit: or

The publication of this information is made for transparency purposes only, as further detailed in the Pfizer EEA HCP Privacy Policy at (section “Disclosures of transfer of value”). It does not entail a general authorisation to those accessing the website to carry out any further processing of health care professionals'  (HCP’s) data, such as combining it with the information published on other websites.

Here in Latvia disclosure of payments, made to HCPs and HCOs during 2018 is available on website

Here in Latvia disclosure of payments, made to HCPs and HCOs during 2019 is available on website

According to the SIFFA and LPMA Code of Good Practice and Ethics (effective as of December 01, 2020) in Latvia reports about the Transfer of Values (ToVs) made to HCPs and HCOs during the year 2020 are submitted by the company to the Health Inspectorate and will be available on the following site by 30 June, 2021

  • 2020 report of values transferred to POs can be found here.
  • Pfizer Self Certification Scheme for 2020 can be found here.
  • Last Review date: June 2020